Details for: CTSL
Associated with
Significant Cells
Cell Significance Index (CSI) scores for the chosen context(s)
-
CSI 73.88rCSI 67.84%PRS 87.31
-
CSI 58.7rCSI 72.61%PRS 77.8
-
CSI 47.19rCSI 59.32%PRS 88.72
-
CSI 45.92rCSI 70.95%PRS 79.01
-
CSI 38rCSI 71.73%PRS 87.68
-
CSI 32.45rCSI 100%PRS 84.22
-
CSI 30.22rCSI 49.78%PRS 83.74
-
CSI 28.49rCSI 26.28%PRS 81.43
-
CSI 23.97rCSI 25.11%PRS 83.16
-
CSI 23.93rCSI 33.92%PRS 76.67
-
CSI 22.96rCSI 66.13%PRS 86.12
-
CSI 21.08rCSI 26.22%PRS 59.95
-
CSI 20.26rCSI 36.86%PRS 86.77
-
CSI 18.32rCSI 17.67%PRS 73.19
-
CSI 18.28rCSI 36.69%PRS 70.16
-
CSI 17.97rCSI 15.49%PRS 80.9
-
CSI 17.64rCSI 17.35%PRS 82.5
-
CSI 17.22rCSI 38.45%PRS 86.77
-
CSI 16.73rCSI 38.26%PRS 80.69
-
CSI 16.54rCSI 40.95%PRS 79.63
-
CSI 15.97rCSI 14.04%PRS 69.17
-
CSI 15.87rCSI 19.76%PRS 88.62
-
CSI 15.78rCSI 35.43%PRS 91.32
-
CSI 15.51rCSI 11.95%PRS 82.67
-
CSI 14.95rCSI 12.15%PRS 79.27
-
CSI 14.64rCSI 23.12%PRS 81.44
-
CSI 12.43rCSI 36%PRS 79.4
-
CSI 12.16rCSI 23.19%PRS 89.24
-
CSI 11.65rCSI 37.27%PRS 77.27
-
CSI 11.48rCSI 20.25%PRS 85.01
-
CSI 10.9rCSI 29.95%PRS 86.63
-
CSI 10.86rCSI 11.33%PRS 79.34
-
CSI 10.49rCSI 25.06%PRS 84.02
-
CSI 10.45rCSI 8.26%PRS 68.69
-
CSI 10.42rCSI 21.62%PRS 76.71
-
CSI 9.96rCSI 9.27%PRS 80.73
-
CSI 9.85rCSI 12.9%PRS 90
-
CSI 9.82rCSI 13.6%PRS 77.24
-
CSI 9.67rCSI 56.24%PRS 83.84
-
CSI 9.08rCSI 14.71%PRS 74.94
-
CSI 9.01rCSI 16.28%PRS 85.12
-
CSI 8.6rCSI 11%PRS 89.58
-
CSI 8.32rCSI 11.06%PRS 85.36
-
CSI 7.92rCSI 12.69%PRS 90.42
-
CSI 7.88rCSI 18.95%PRS 83.16
-
CSI 7.74rCSI 17.67%PRS 71.48
-
CSI 7.74rCSI 10.58%PRS 84.25
-
CSI 7.41rCSI 29.84%PRS 81.55
-
CSI 6.95rCSI 15.57%PRS 62.77
-
CSI 6.94rCSI 32.08%PRS 91.44
-
CSI 6.85rCSI 15.07%PRS 83.62
-
CSI 6.84rCSI 15.51%PRS 80.44
-
CSI 6.66rCSI 6.89%PRS 84.02
-
CSI 6.51rCSI 15.91%PRS 72.38
-
CSI 6.51rCSI 6.27%PRS 79.27
-
CSI 6.51rCSI 27.37%PRS 85.46
-
CSI 6.36rCSI 16.79%PRS 86.38
-
CSI 6.32rCSI 6.92%PRS 81.75
-
CSI 6.31rCSI 4.68%PRS 73.52
-
CSI 6.26rCSI 9.57%PRS 87.04
-
CSI 6.2rCSI 13.72%PRS 79.29
-
CSI 6.03rCSI 26.78%PRS 80.44
-
CSI 5.94rCSI 9.48%PRS 71.56
-
CSI 5.9rCSI 19.12%PRS 78.05
-
CSI 5.87rCSI 63.85%PRS 90.01
-
CSI 5.68rCSI 6.09%PRS 81.21
-
CSI 5.62rCSI 11.14%PRS 85.39
-
CSI 5.58rCSI 9.54%PRS 93.82
-
CSI 5.58rCSI 9.13%PRS 69.5
-
CSI 5.54rCSI 7.7%PRS 78.44
-
CSI 5.51rCSI 8.32%PRS 85.05
-
CSI 5.47rCSI 7.47%PRS 79.71
-
CSI 5.44rCSI 6.99%PRS 70.22
-
CSI 5.44rCSI 29.27%PRS 87.61
-
CSI 5.32rCSI 7.68%PRS 85.43
-
CSI 5.29rCSI 8.52%PRS 69.98
-
CSI 5.23rCSI 7.13%PRS 71.57
-
CSI 5.2rCSI 30.57%PRS 86.36
-
CSI 5.14rCSI 6.54%PRS 84.78
-
CSI 5.12rCSI 5.11%PRS 73.78
-
CSI 5.05rCSI 11.85%PRS 79.99
-
CSI 5.02rCSI 7.16%PRS 80.74
-
CSI 4.88rCSI 9.48%PRS 82.86
-
CSI 4.82rCSI 18.06%PRS 72.37
-
CSI 4.57rCSI 29.39%PRS 88.62
-
CSI 4.34rCSI 12.21%PRS 74.97
-
CSI 4.34rCSI 17.26%PRS 86.99
-
CSI 4.29rCSI 20.54%PRS 79.82
-
CSI 4.23rCSI 10.75%PRS 73.22
-
CSI 4.21rCSI 6.69%PRS 88.37
-
CSI 4.11rCSI 5%PRS 86.32
-
CSI 4.11rCSI 4.29%PRS 77.57
-
CSI 4.01rCSI 25.07%PRS 71.53
-
CSI 3.86rCSI 3%PRS 92.65
-
CSI 3.83rCSI 2.75%PRS 91.43
-
CSI 3.81rCSI 4.4%PRS 72.3
-
CSI 3.72rCSI 4.97%PRS 86.02
-
CSI 3.7rCSI 16.99%PRS 84.42
-
CSI 3.65rCSI 20.34%PRS 83.27
-
CSI 3.63rCSI 38.45%PRS 76.42
-
CSI 0.2rCSI 4.7%PRS 90.2%
-
CSI 0.4rCSI 2.2%PRS 90.6%
-
CSI 0.5rCSI 12.3%PRS 88.5%
-
CSI 0.5rCSI 11.4%PRS 88.5%
-
CSI 0.5rCSI 4.9%PRS 95.3%
-
CSI 0.6rCSI 3.5%PRS 84.9%
-
CSI 0.7rCSI 4.7%PRS 86.6%
-
CSI 0.7rCSI 5.7%PRS 88.6%
-
CSI 0.8rCSI 2.0%PRS 85.5%
-
CSI 0.8rCSI 2.8%PRS 87.8%
-
CSI 0.9rCSI 2.2%PRS 70.4%
-
CSI 0.9rCSI 4.1%PRS 88.2%
-
CSI 0.9rCSI 6.5%PRS 88.1%
-
CSI 0.9rCSI 2.7%PRS 86.7%
-
CSI 1.0rCSI 4.7%PRS 90.7%
-
CSI 1.2rCSI 2.0%PRS 62.0%
-
CSI 1.3rCSI 10.2%PRS 74.1%
-
CSI 1.3rCSI 5.9%PRS 89.3%
-
CSI 1.3rCSI 4.2%PRS 63.7%
-
CSI 1.4rCSI 1.7%PRS 63.1%
-
CSI 1.4rCSI 6.2%PRS 87.9%
-
CSI 1.4rCSI 3.3%PRS 80.2%
-
CSI 1.4rCSI 2.5%PRS 61.4%
-
CSI 1.5rCSI 2.3%PRS 83.6%
-
CSI 1.5rCSI 2.1%PRS 91.8%
-
CSI 1.5rCSI 5.8%PRS 79.6%
-
CSI 1.5rCSI 2.4%PRS 72.9%
-
CSI 1.5rCSI 2.8%PRS 68.4%
-
CSI 1.5rCSI 4.0%PRS 78.6%
-
CSI 1.6rCSI 3.5%PRS 65.7%
-
CSI 1.6rCSI 4.0%PRS 85.0%
-
CSI 1.6rCSI 5.2%PRS 81.9%
-
CSI 1.6rCSI 5.3%PRS 76.8%
-
CSI 1.8rCSI 3.4%PRS 92.8%
-
CSI 2.0rCSI 2.7%PRS 82.0%
-
CSI 2.0rCSI 45.7%PRS 91.4%
-
CSI 2.0rCSI 3.1%PRS 76.7%
-
CSI 2.1rCSI 1.7%PRS 80.6%
-
CSI 2.1rCSI 1.9%PRS 77.6%
-
CSI 2.2rCSI 3.9%PRS 79.1%
-
CSI 2.2rCSI 5.2%PRS 83.8%
-
CSI 2.2rCSI 2.3%PRS 77.4%
-
CSI 2.2rCSI 4.5%PRS 89.1%
-
CSI 2.2rCSI 3.0%PRS 71.6%
-
CSI 2.2rCSI 5.1%PRS 73.8%
-
CSI 2.2rCSI 7.2%PRS 77.7%
-
CSI 2.3rCSI 5.4%PRS 80.3%
-
CSI 2.3rCSI 5.9%PRS 87.0%
-
CSI 2.3rCSI 15.0%PRS 86.9%
-
CSI 2.3rCSI 6.0%PRS 75.4%
-
CSI 2.4rCSI 5.5%PRS 90.2%
-
CSI 2.4rCSI 3.5%PRS 84.6%
-
CSI 2.5rCSI 2.9%PRS 83.8%
-
CSI 2.5rCSI 9.1%PRS 59.9%
-
CSI 2.5rCSI 3.8%PRS 83.7%
-
CSI 2.6rCSI 28.1%PRS 85.3%
-
CSI 2.6rCSI 6.7%PRS 81.1%
-
CSI 2.6rCSI 14.6%PRS 88.8%
-
CSI 2.6rCSI 5.3%PRS 75.7%
-
CSI 2.7rCSI 2.1%PRS 95.0%
-
CSI 2.7rCSI 2.1%PRS 83.6%
-
CSI 2.7rCSI 4.1%PRS 83.7%
-
CSI 2.7rCSI 6.5%PRS 60.0%
-
CSI 2.7rCSI 3.3%PRS 87.3%
-
CSI 2.7rCSI 12.1%PRS 68.5%
-
CSI 2.8rCSI 4.2%PRS 80.0%
-
CSI 2.8rCSI 4.3%PRS 80.2%
-
CSI 2.9rCSI 8.9%PRS 66.0%
-
CSI 2.9rCSI 10.8%PRS 62.5%
-
CSI 2.9rCSI 4.2%PRS 88.9%
-
CSI 2.9rCSI 11.8%PRS 79.6%
-
CSI 2.9rCSI 5.1%PRS 71.6%
-
CSI 3.0rCSI 3.6%PRS 77.6%
-
CSI 3.1rCSI 18.1%PRS 62.7%
-
CSI 3.2rCSI 5.6%PRS 73.8%
-
CSI 3.3rCSI 5.4%PRS 63.6%
-
CSI 3.5rCSI 19.0%PRS 85.8%
-
CSI 3.5rCSI 5.2%PRS 74.6%
-
CSI 3.6rCSI 6.4%PRS 73.3%
-
CSI 3.6rCSI 17.7%PRS 87.4%
-
CSI 3.6rCSI 38.5%PRS 76.4%
-
CSI 3.7rCSI 20.3%PRS 83.3%
-
CSI 3.7rCSI 17.0%PRS 84.4%
-
CSI 3.7rCSI 5.0%PRS 86.0%
-
CSI 3.8rCSI 4.4%PRS 72.3%
-
CSI 3.8rCSI 2.8%PRS 91.4%
-
CSI 3.9rCSI 3.0%PRS 92.7%
-
CSI 4.0rCSI 25.1%PRS 71.5%
-
CSI 4.1rCSI 4.3%PRS 77.6%
-
CSI 4.1rCSI 5.0%PRS 86.3%
-
CSI 4.2rCSI 6.7%PRS 88.4%
-
CSI 4.2rCSI 10.8%PRS 73.2%
-
CSI 4.3rCSI 20.5%PRS 79.8%
-
CSI 4.3rCSI 17.3%PRS 87.0%
-
CSI 4.3rCSI 12.2%PRS 75.0%
-
CSI 4.6rCSI 29.4%PRS 88.6%
-
CSI 4.8rCSI 18.1%PRS 72.4%
-
CSI 4.9rCSI 9.5%PRS 82.9%
-
CSI 5.0rCSI 7.2%PRS 80.7%
-
CSI 5.1rCSI 11.9%PRS 80.0%
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration
Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.
Legend:
- Query Gene
-
Node Color (Target Cell CSI, relative to current network):
- Very High
- High
- Medium
- Low
- Very Low
- CSI N/A
- Node Size: Proportional to Target Cell CSI magnitude
- STRING PPI Edge
- Shared Pathway Edge (ONTOLOGY)
Other Information
This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.
Genular Protein ID: 1142374600
Symbol: CATL1_HUMAN
Name: Major excreted protein
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 3421948
Title: Isolation and sequence of a cDNA for human pro-(cathepsin L).
PubMed ID: 3421948
DOI: 10.1042/bj2530303
PubMed ID: 2835398
Title: Complete nucleotide and deduced amino acid sequences of human and murine preprocathepsin L. An abundant transcript induced by transformation of fibroblasts.
PubMed ID: 2835398
DOI: 10.1172/jci113497
PubMed ID: 17974005
Title: The full-ORF clone resource of the German cDNA consortium.
PubMed ID: 17974005
PubMed ID: 15164053
Title: DNA sequence and analysis of human chromosome 9.
PubMed ID: 15164053
DOI: 10.1038/nature02465
PubMed ID: 15489334
Title: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
PubMed ID: 15489334
DOI: 10.1101/gr.2596504
PubMed ID: 3342889
Title: Amino acid sequences of the human kidney cathepsins H and L.
PubMed ID: 3342889
PubMed ID: 3550705
Title: The major ras induced protein in NIH3T3 cells is cathepsin L.
PubMed ID: 3550705
PubMed ID: 3545185
Title: The N-terminal amino acid sequences of the heavy and light chains of human cathepsin L. Relationship to a cDNA clone for a major cysteine proteinase from a mouse macrophage cell line.
PubMed ID: 3545185
DOI: 10.1042/bj2400373
PubMed ID: 9468501
Title: Autocatalytic processing of recombinant human procathepsin L. Contribution of both intermolecular and unimolecular events in the processing of procathepsin L in vitro.
PubMed ID: 9468501
PubMed ID: 10716919
Title: Secreted cathepsin L generates endostatin from collagen XVIII.
PubMed ID: 10716919
PubMed ID: 12754519
Title: Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry.
PubMed ID: 12754519
DOI: 10.1038/nbt827
PubMed ID: 15099520
Title: A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor.
PubMed ID: 15099520
PubMed ID: 16335952
Title: Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.
PubMed ID: 16335952
DOI: 10.1021/pr0502065
PubMed ID: 16081529
Title: Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.
PubMed ID: 16081529
PubMed ID: 16339146
Title: SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells.
PubMed ID: 16339146
PubMed ID: 18562523
Title: Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide.
PubMed ID: 18562523
DOI: 10.1128/jvi.00415-08
PubMed ID: 19159218
Title: Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry.
PubMed ID: 19159218
DOI: 10.1021/pr8008012
PubMed ID: 21269460
Title: Initial characterization of the human central proteome.
PubMed ID: 21269460
PubMed ID: 22905912
Title: Resveratrol-induced changes of the human adipocyte secretion profile.
PubMed ID: 22905912
DOI: 10.1021/pr300539b
PubMed ID: 24275569
Title: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.
PubMed ID: 24275569
PubMed ID: 26953343
Title: Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).
PubMed ID: 26953343
PubMed ID: 30425301
Title: Deficiency of the human cysteine protease inhibitor cystatin M/E causes hypotrichosis and dry skin.
PubMed ID: 30425301
PubMed ID: 32142651
Title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.
PubMed ID: 32142651
PubMed ID: 32361028
Title: Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment.
PubMed ID: 32361028
PubMed ID: 32221306
Title: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.
PubMed ID: 32221306
PubMed ID: 32855215
Title: MHC class II transactivator CIITA induces cell resistance to Ebola virus and SARS-like coronaviruses.
PubMed ID: 32855215
PubMed ID: 34159616
Title: TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells.
PubMed ID: 34159616
PubMed ID: 8896443
Title: Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment.
PubMed ID: 8896443
PubMed ID: 9141479
Title: The crystal structure of human cathepsin L complexed with E-64.
PubMed ID: 9141479
Sequence Information:
- Length: 333
- Mass: 37564
- Checksum: 8CD17D00EF859D85
- Sequence:
MNPTLILAAF CLGIASATLT FDHSLEAQWT KWKAMHNRLY GMNEEGWRRA VWEKNMKMIE LHNQEYREGK HSFTMAMNAF GDMTSEEFRQ VMNGFQNRKP RKGKVFQEPL FYEAPRSVDW REKGYVTPVK NQGQCGSCWA FSATGALEGQ MFRKTGRLIS LSEQNLVDCS GPQGNEGCNG GLMDYAFQYV QDNGGLDSEE SYPYEATEES CKYNPKYSVA NDTGFVDIPK QEKALMKAVA TVGPISVAID AGHESFLFYK EGIYFEPDCS SEDMDHGVLV VGYGFESTES DNNKYWLVKN SWGEEWGMGG YVKMAKDRRN HCGIASAASY PTV
Genular Protein ID: 178632525
Symbol: Q9HBQ7_HUMAN
Name: N/A
UniProtKB Accession Codes:
Database IDs:
Citations:
PubMed ID: 11181995
Sequence Information:
- Length: 151
- Mass: 16839
- Checksum: 539C686EE95C80B3
- Sequence:
MDYAFQYVQD NGGLDSEESY PYEATEESCK YNPKYSVAND TGFVDIPKQE KALMKAVATV GPISVAIDAG HESFLFYKEG IYFEPDCSSE DMDHGVLVVG YGFESTESDN NKYWLVKNSW GEEWGMGGYV KMAKDRRNHC GIASAASYPT V